German scientific council plays up PET (positron emission tomography) potential:
This article was originally published in Clinica
Executive Summary
The German government's scientific council (Wissenschaftsrat) has urged hospitals and clinics to push for positron emission tomogrophy (PET) to be included in the catalogue of reimbursable procedures. It claims that increased clinical use of PET over the past 10 years has contributed greatly to the diagnosis of cancerous tumours and coronary heart disease, as well as neurological diseases such as epilepsy, Parkinson's and Alzheimer's disease. The Wissenschaftsrat has, however, said that the scientific potential that PET offers as a biochemical in vivo analysis method is only in the preliminary stage of development. It therefore suggests that in future PET investment for research purposes should be concentrated around PET centres of excellence that are able to exploit its use to the maximum.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.